CWC
MRNA icon

Carolinas Wealth Consulting’s Moderna MRNA Stock Holding History

Carolinas Wealth Consulting’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$284 – 595
2025
Q1 		$284 Sell
10
-5
-33% -$177 ﹤0.01% 993
2024
Q4 		$624 Buy
15
+3
+25% +$143 ﹤0.01% 987
2024
Q3 		$802 Hold
12
– – ﹤0.01% 953
2024
Q2 		$1.43K Hold
12
– – ﹤0.01% 857
2024
Q1 		$1.28K Buy
+12
New +$1.21K ﹤0.01% 852
2023
Q3 		– Sell
-4
Closed -$486 – 1083
2023
Q2 		$486 Buy
+4
New +$534 ﹤0.01% 993
2023
Q1 		– Sell
-6
Closed -$1.08K – 1100
2022
Q4 		$1.08K Buy
+6
New +$981 ﹤0.01% 885
2022
Q3 		– Sell
-3
Closed – – 924
2022
Q2 		$0 Sell
3
-12
-80% -$1.72K ﹤0.01% 931
2022
Q1 		$3K Sell
15
-6
-29% -$1.01K ﹤0.01% 764
2021
Q4 		$5K Buy
21
+15
+250% +$4.39K ﹤0.01% 711
2021
Q3 		$2K Buy
+6
New +$2.21K ﹤0.01% 801
2021
Q2 		– Sell
-257
Closed -$34K – 980
2021
Q1 		$34K Hold
257
– – 0.01% 425
2020
Q4 		$27K Hold
257
– – 0.01% 432
2020
Q3 		$18K Buy
+257
New +$17.9K 0.01% 404

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Carolinas Wealth Consulting's MRNA Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Moderna (MRNA) in Q2 2025, closing a stake of 10 shares — an estimated $284 sold.

Carolinas Wealth Consulting first reported a position in MRNA in Q3 2020 and held it in 14 quarters. The position peaked at $34K in Q1 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 10 Moderna shares in Q2 2025, an estimated $284.
  • Carolinas Wealth Consulting first reported a position in Moderna in Q3 2020 and held it in 14 quarters.
  • Carolinas Wealth Consulting's Moderna position peaked at $34K in Q1 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.